UK Vaccines Business Pushes Wockhardt To Sales Growth
Company ‘Makes about 80% Of The AstraZeneca Vaccine’
Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.
You may also be interested in...
India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.
In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?